Thalidomide

Generic Name
Thalidomide
Brand Names
Thalomid, Thalidomide BMS (previously Thalidomide Celgene), Thalidomide Lipomed
Drug Type
Small Molecule
Chemical Formula
C13H10N2O4
CAS Number
50-35-1
Unique Ingredient Identifier
4Z8R6ORS6L
Background

A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators li...

Indication

Thalidomide is primarily used for the acute treatment and maintenance therapy to prevent and suppress the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL).

Associated Conditions
Aphthous Stomatitis, Chronic Graft-Versus-Host Disease, Erythema Nodosum Leprosum, Multiple Myeloma (MM), Primary Amyloidosis, Uremic Pruritus, Waldenström's Macroglobulinemia (WM), Moderate Erythema nodosum leprosum, Refractory Graft versus host disease, Severe Erythema nodosum leprosum, Treatment naive multiple myeloma
Associated Therapies
-
Clinical Trials
Related News

Epirubicin and Thalidomide in Treating Patients With Liver Cancer

Phase 2
Completed
Conditions
Liver Cancer
First Posted Date
2003-04-09
Last Posted Date
2013-07-18
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
12
Registration Number
NCT00058487
Locations
🇺🇸

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

🇺🇸

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States

Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

First Posted Date
2003-02-06
Last Posted Date
2022-10-03
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
24
Registration Number
NCT00054158
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People

Phase 2
Completed
Conditions
HIV Infections
Interventions
Drug: Thalidomide placebo
Drug: Thalidomide
First Posted Date
2003-01-30
Last Posted Date
2009-08-07
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
40
Registration Number
NCT00053430
Locations
🇺🇸

University of Miami School of Medicine, Miami, Florida, United States

Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS

First Posted Date
2003-01-28
Last Posted Date
2010-06-10
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
42
Registration Number
NCT00053287
Locations
🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome

First Posted Date
2003-01-28
Last Posted Date
2013-06-26
Lead Sponsor
Fallon Clinic
Registration Number
NCT00053001
Locations
🇺🇸

UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, United States

🇺🇸

Fallon Clinic at Worcester Medical Center, Worcester, Massachusetts, United States

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-28
Last Posted Date
2010-06-10
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
30
Registration Number
NCT00053300
Locations
🇺🇸

Josephine Ford Cancer Center at Henry Ford Hospital, Detroit, Michigan, United States

🇺🇸

Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer

First Posted Date
2003-01-27
Last Posted Date
2015-10-28
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
39
Registration Number
NCT00019747
Locations
🇺🇸

Suburban Hospital Cancer Program, Bethesda, Maryland, United States

🇺🇸

Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States

🇺🇸

Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

and more 3 locations

Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2003-01-27
Last Posted Date
2021-09-09
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
46
Registration Number
NCT00025285
Locations
🇺🇸

CCOP - Upstate Carolina, Spartanburg, South Carolina, United States

🇺🇸

Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States

🇺🇸

CCOP - Central Illinois, Decatur, Illinois, United States

and more 2 locations

Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome

First Posted Date
2003-01-27
Last Posted Date
2013-01-31
Lead Sponsor
Roswell Park Cancer Institute
Registration Number
NCT00030550
Locations
🇺🇸

PPD Development, Wilmington, North Carolina, United States

Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma

Phase 2
Conditions
Sarcoma
First Posted Date
2003-01-27
Last Posted Date
2014-01-06
Lead Sponsor
Herbert Irving Comprehensive Cancer Center
Registration Number
NCT00026416
Locations
🇺🇸

Herbert Irving Comprehensive Cancer Center, New York, New York, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy